

(use as many sheets as necessary)


COMPLETE IF KNOWN

Application Number	
Filing Date	
First Named Inventor	
Group Art Unit	
Examiner Name	
Attorney Docket Number	21414

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
 N.C./		EP	532 456		Ciba Geigy	12/08/1991
		WO	98 31677		Pierre Fabre	07/23/1998
		WO	97 45119		Novartis Ag	12/04/1997
		WO	98 05336		SmithKline Beecham Corporation	02/12/1998
		WO	94 21615		Merck Sharp & Dohme	09/29/1994
		DE	4241632		Dr. Karl Thomas GmbH	06/16/1994
		FR 2758328 (English language abstract)			Pierre Fabre	01/15/1997
		WO	99 51589		Hoechst Schering	03/23/1999
		WO	97 43279		Jannsen	11/02/1997
N.C./		FR 2758327 (English language abstract)			Pierre Fabre	01/15/1997
Examiner Signature	/Nizal Chandrakumar/				Date Considered	05/13/2009

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. 12/1/2007

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

COMPLETE IF KNOWN

Sheet	2	of	2	Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	21414

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
N.C.		Danysz, W., et al., Pharmacological Rev., Vol. 50, pp. 597-664, 1998
		Dickenson, A., TIPS, Vol. 11, pp. 307-309, 1990
		Wenzel, A., et al., Neurochemistry, Vol. 7, pp. 45-48, 1995
		Kew, J. N. C., et al., Brit. J. Pharmacology, Vol. 123, pp. 463-472, 1998
		Boyce, S., et al., Neuropharmacology, Vol. 38, pp. 611-623, 1999
		Laurie, D. J., et al., Mol. Brain Res., Vol. 51, pp. 23-32, 1997
		Ishii, T., et al., J. Biol. Chem., Vol. 268, pp. 2836-2843, 1993
		Max, M. B., et al., Clin. Neuropharmacology, Vol. 18, pp. 360-368, 1995
		Knox, D. J., et al., Anaesth. Intens. Care, Vol. 23, pp. 620-622, 1995
		Eide, P. K., et al., Pain, Vol. 61, pp. 221-228, 1995
		Kristensen, J. D., et al., Pain, Vol. 51, pp. 249-253, 1992
		Taniguchi, K, et al., Brit. J. Pharmacology, Vol. 122, pp. 809-812, 1997
		Isabelle Parrot, et al., Synthesis of Substituted 3-Amino-6-Arylpyridazines via Suzuki Reaction, Vol. 7, pp. 1163-1168, 1999
N.C.		J. Moragues, et al., Dopaminergic Activity in a Series of N-substituted 2-Aminopyrimides, Vol. 35, pp. 951-964, 1980

Examiner Signature	/Nizal Chandrakumar/	Date Considered	05/13/2009
--------------------	----------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 12/1/2007